Navigation Links
Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Progenitor Cell Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), today announced key additions to its management team to meet the demands associated with its contract development and manufacturing activities, including those associated with NeoStem's other subsidiaries, which add to the PCT client list.  NeoStem is an international biopharmaceutical company with a focus on cell-based therapeutic development, and, through its acquisition of PCT, is solidifying its position as a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, PCT, and global reach has positioned the Company for important advances in the cell therapy industry.  The success of PCT's client business has allowed the Company to expand its management and technical staff in order to grow revenue and advance these cell therapies towards commercialization.  

Timothy Fong, PhD, MBA, formerly of BD Biosciences, is joining PCT as Vice President, Technology and Product Development. David O'Neill, MD, formerly of New York University Medical Center, was recently appointed Director of Research and Development for the Company.

Dr. Fong brings with him significant experience from his previous position as Technical Director of the Cell Therapy Research Team, BD Biosciences, where, as part of the cell therapy enablement team, he was responsible for the development and manufacturing of conjugated antibody reagents for use in cell sorting for clinical cell therapeutic products. Prior to that role, Dr. Fong led a team at BD Biosciences in the development of a T Regulatory cell product for the treatment of GvHD and autoimmune diseases. This technology has since been licensed by NeoStem's Athelos subsidiary. While
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
3. Progenitor Cell Therapy Appoints VP of Manufacturing Operations
4. Progenitor Cell Therapy Expands Manufacturing Operations
5. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
6. NeoStem Acquires Progenitor Cell Therapy
7. Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1
8. Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military
9. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
10. JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media
11. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that Innovative ... e-Journal and producer of Food Labs Conference , ... the co-location of Food Labs Conference to be held in ... fee to attend the two-day Food Lab Conference, March 4-5. ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Rao and his team are researching nano-scale cantilevers that have ... or gases in the air. Put them into a small ... alerts in battle, in industry, in health care and even ... to do this work has been something we,ve only seen ...
... 98% and Adjusted EBITDA Up 70% Year-Over-Year, ... Inc. (NYSE: WX ), a leading pharmaceutical, ... with operations,in China and the United States, today ... ended September 30, 2008. During the quarter,WuXi,s net ...
... announced today the successful closure of its Starfish ... capital fundraising in,Australia. The fund will invest in ... of this fundraising is an endorsement of Starfish ... the development of,innovative companies that, with the right ...
Cached Biology Technology:Clemson researchers advance nanoscale electromechanical sensors 2WuXi PharmaTech Announces Third Quarter 2008 Results 2WuXi PharmaTech Announces Third Quarter 2008 Results 3WuXi PharmaTech Announces Third Quarter 2008 Results 4WuXi PharmaTech Announces Third Quarter 2008 Results 5WuXi PharmaTech Announces Third Quarter 2008 Results 6WuXi PharmaTech Announces Third Quarter 2008 Results 7WuXi PharmaTech Announces Third Quarter 2008 Results 8WuXi PharmaTech Announces Third Quarter 2008 Results 9WuXi PharmaTech Announces Third Quarter 2008 Results 10WuXi PharmaTech Announces Third Quarter 2008 Results 11WuXi PharmaTech Announces Third Quarter 2008 Results 12WuXi PharmaTech Announces Third Quarter 2008 Results 13Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund 2
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia ... makes testing safer, easier, faster and cheaper. , ... is commonly found in soils all over the world ... both humans and animals. The bacteria can survive in ... B. anthracis may occur through skin contact, inhalation ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... honored Clemson professor Rajendra Singh Thursday as a ... and expand solar deployment in the residential, commercial ... Banks Professor of Electrical and Computer Engineering and ... considered a local hero leading the charge across ... in solar power and driving policy changes at ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3Patented research remotely detects nitrogen-rich explosives 2White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... are the most populous organisms on the planet. They ... habitats by means of genetic variations that provide the ... what scientists believe is a random mutation and exchange ... that sometimes confers an advantage, and which then becomes ...
... to experience a "moderate" regional "red tide" this spring and ... to study the toxic algae that causes the bloom. The ... beings, however the toxins they produce can accumulate in filter-feeding ... shellfish poisoning (PSP) in humans who consume them. Under ...
... honored as the 2012 recipient of the ACMG Foundation/Signature ... College of Medical Genetics (ACMG) 2012 Annual Clinical Genetics ... for the award for her platform presentation, "Triheptanoin Therapy ... Ms. Barone will complete her Doctor of Medicine degree ...
Cached Biology News:Study shows unified process of evolution in bacteria and sexual eukaryotes 2Study shows unified process of evolution in bacteria and sexual eukaryotes 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 2Researchers report potential for a 'moderate' New England 'red tide' in 2012 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 42012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced 2
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
DTT, 25g...
... Agarose overlays are commonly ... Many commercial "DNA grade" agaroses ... toxic to insect cells or ... to obtain good overlays. Novagen's ...
Biology Products: